Chinese Academy of Sciences

Suzhou Suplead Life Sciences Co., Ltd.

Suzhou Institute of Materia Medica

Gang Qiao

Hualiang Jiang

Cheng Luo

Bing Zhou

Yaxi Yang

Shijie Chen

Xinjun Wang

Senhao Xiao

Hong Ding

Yuanyuan Zhang

Daohai Du

Zizhou Li

Lianghe Mei

Wenchao Lu

Shili Wan

Rukang Zhang

Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.

Histone acetyltransferase (HAT) inhibitor and use thereof

The present invention relates to a bromodomain inhibitor. Provided are a compound represented by general formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, racemate, polymorph, solvate, or isotopically labeled compound (including deuterium substitution) thereof, a preparation method of the same, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. 

Bromodomain inhibitor compound and use thereof

The present invention provides a compound represented by formula I, pharmaceutically acceptable salts, enantiomers, diastereomers or racemates thereof, the preparation method thereof, the pharmaceutical composition comprising the same, and the use thereof in the preparation of a medicament for treating a disease or condition mediated by EED and/or PRC2. The compound of the present invention can be used treating PRC2-mediated diseases or conditions. 

Triazolopyrimidine, triazolopyridine compounds, and the composition thereof for treating PRC2-mediated diseases

Growing community of inventors

Jiangsu, China

Gang Qiao